Elon to replace the dollar?

Analyst Targets

• Morgan Stanley: Equalweight, target raised to $233 from $205 (November 3)
• Oppenheimer: Buy, target $235 (November 2)
• Cantor Fitzgerald: Neutral, target raised to $207 from $156 (November 2)
• Rosenblatt: Buy, target $260 (October 27)
• Barclays: Buy, target $265 (October 29)
• Jefferies: Underperform, target $80

The Quarter

Palantir reported after Monday’s close and, on every headline metric, it was genuinely exceptional. Revenue of $2.313 billion beat the roughly $2.18 billion consensus and grew 96% year over year, the company’s fastest annual rate. Adjusted EPS of $0.44 topped the $0.41 estimate. GAAP operating income crossed $1 billion for the first time, landing at $1.085 billion on a 47% margin. Adjusted operating margin held at 62%.

Management raised full-year revenue guidance to $8.530–$8.534 billion, up from $8.15–$8.16 billion, and lifted U.S. commercial revenue guidance to in excess of $3.559 billion, implying at least 143% annual growth. By any conventional measure, this was a beat-and-raise of the first order.

PLTR still closed Monday’s session down 3.13% to $178.34, then fell further after hours before partially recovering.

Why the Stock Fell

The number that mattered was not in the headline. U.S. commercial total contract value, the value of new deals signed during the quarter, came in at $1.463 billion, up just 11% year over year. One quarter earlier, the same metric had grown 153%, with a then-record $2.132 billion signed. The sequential drop was 31.4%.

That divergence is the entire debate. Revenue growing at 148% while new contract signings grow at 11% means Palantir is converting its backlog at an extraordinary rate but replenishing it far more slowly. U.S. commercial remaining deal value of $6.517 billion rose only 4% sequentially, and total TCV across all segments grew just 6% year over year, down from 49% in Q2.

The tension between reported revenue and forward booking health is not unique to Palantir. Snowflake’s consumption model makes net revenue retention the most honest signal of whether AI spend is actually pulling through the platform.

Bears read this as a leading indicator: today’s revenue is being pulled forward from a pipeline that is not refilling at the same speed. Bulls counter that contract duration is compressing as enterprise clients shift from multi-year commitments to shorter, faster deployments, which compresses reported TCV without reducing underlying demand. The remaining deal value figure, still up 79% annually, partially supports that argument.

The backlog-versus-bookings tension is not unique to Palantir. Oracle’s $638 billion remaining performance obligations raised the same question about whether contracted revenue pipelines reflect real demand or deferred risk.

Business Mix and Macro Context

One structural milestone is worth noting regardless of the contract debate. U.S. commercial revenue of $984 million exceeded U.S. government revenue of $953 million for the first time in Palantir’s history. The commercial business expanded 148% annually and 29% sequentially, while government grew 96% annually. U.S. revenue overall was $1.937 billion, representing 84% of total revenue. International commercial grew 21% annually and was up 1% sequentially, a meaningful contrast to the domestic pace.

The AI software sector broadly is navigating a transition from land-and-expand to scale-and-sustain. Peers like ServiceNow and Datadog have also faced scrutiny over whether enterprise AI contract velocity can keep pace with reported revenue acceleration. For Palantir specifically, with a simplified enterprise value not specified here and a stock that traded at a record just under $213 in mid-October, the valuation leaves no margin for ambiguity in the forward booking numbers.

Bull / Base / Bear

Bull: Shorter contract durations are a product mix shift, not a demand signal. Full-year commercial revenue guidance raised to in excess of $3.559 billion reflects genuine pipeline visibility. Rule of 40 at 158% and $1.216 billion in quarterly free cash flow confirm the platform’s operating leverage. A re-rating toward $230–$260 is achievable if Q4 TCV rebounds.

Base: Revenue execution continues, but TCV growth remains subdued through H1 2027 as enterprises digest large prior deployments. Stock consolidates in the $165–$195 range while the market waits for bookings evidence. Q4 revenue guidance midpoint of roughly $2.651 billion provides a near-term anchor.

Bear: The 11% TCV growth is a genuine inflection, not a duration artifact. If the U.S. commercial pipeline is saturating at current penetration levels, revenue growth decelerates materially in 2027. At current multiples, that scenario implies significant downside toward the $130–$150 range.

Technical Overlay

PLTR broke its 50-day moving average on Monday’s close and is now trading well below the $213 record set in mid-October. The $178 level is the immediate area of interest; a sustained hold below it opens a path toward the $165 zone, which marks the prior consolidation base from early October. A recovery above $188 would be the first signal that the post-earnings sellers have been absorbed.

What to Watch

• Q4 U.S. commercial TCV: the single figure that resolves the core debate
• Customer count growth and trailing 12-month revenue per customer, which grew 88% annually in Q3
• Analyst revisions following Morgan Stanley’s target hike to $233 despite its Hold-equivalent rating
• Sector read-across from ServiceNow and Salesforce as enterprise AI contract data accumulates

Bottom Line

Palantir delivered a historically strong quarter. The problem is that the market had already priced one in. At $178, PLTR is being asked a different question than it was at $213: not whether the AI platform works, but whether the funnel of new enterprise commitments is wide enough to justify a valuation that demands perpetual outperformance. The 11% TCV growth rate is the only number that matters until Q4 proves otherwise.